Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

268
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
268
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

867
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
867
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.3K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reach of Palliative Care in Parkinson Disease: Progress and Gaps After a National Team-Based Implementation Project.

Neurology. Clinical practice·2026
Same author

Multisite study: Predicting Lewy body disease using skin biopsy α-synuclein seed amplification assays.

Journal of neuropathology and experimental neurology·2026
Same author

Essential genetic testing in movement disorders - results from a Delphi study.

Parkinsonism & related disorders·2026
Same author

Embedding Palliative Care Clinicians in ALS Teams Improves ALS Clinicians' Confidence in Their Patient Management and Satisfaction With Palliative Care.

Muscle & nerve·2026
Same author

Expanding PPMI through Remote Data Acquisition and Analysis: Early Success and Future Growth with myPPMI.

Annals of neurology·2026
Same author

Domains of Caregiving in Parkinson's Disease: A Framework Developed Through Perspective Mapping.

The American journal of hospice & palliative care·2026
Same journal

Comment on: "Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease".

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

A Phase 1 Study of Convection-Enhanced Delivery of Intraputaminal AAV2-GDNF in Advanced Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Reply to Comment on: "Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease".

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Gene Therapy for Amino Acid Decarboxylase Deficiency: Clinical and Imaging Outcomes in a French Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Hyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study.

Movement disorders : official journal of the Movement Disorder Society·2026
See all related articles

Related Experiment Video

Updated: Dec 25, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Progressive Supranuclear Palsy and Statin Use.

Ece Bayram1, Connie Marras2, David G Standaert3

  • 1Movement Disorders Center, Department of Neurosciences, University of California San Diego, San Diego, CA, USA.

Movement Disorders : Official Journal of the Movement Disorder Society
|March 29, 2020
PubMed
Summary
This summary is machine-generated.

Statins may reduce the risk and motor impairment in progressive supranuclear palsy (PSP). Further research is needed to confirm these findings for neuroprotection in tauopathy.

Keywords:
case-controlprogressive supranuclear palsystatinstauopathy

More Related Videos

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

11.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K

Related Experiment Videos

Last Updated: Dec 25, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

11.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K

Area of Science:

  • Neurology
  • Neuroscience
  • Pharmacology

Background:

  • Statins are known for their cholesterol-lowering effects and potential neuroprotective properties.
  • The impact of statins on progressive supranuclear palsy (PSP), a neurodegenerative disease characterized by tauopathy, remains largely unexplored.

Purpose of the Study:

  • To investigate the association between statin use and the risk, onset age, and clinical features of progressive supranuclear palsy (PSP).

Main Methods:

  • The study analyzed data from 284 PSP cases and 284 matched controls from the ENGENE-PSP cohort.
  • Participants were assessed using various clinical scales including the PSP Rating Scale and Unified Parkinson's Disease Rating Scale.
  • Statistical models were employed to examine the relationship between statin use and PSP characteristics.

Main Results:

  • Univariate analysis indicated a lower risk of PSP among users of type 1 statins (simvastatin, lovastatin, pravastatin).
  • After adjusting for confounders, the association between statin use and reduced PSP risk was a trend.
  • Type 1 statins were linked to a 1-year older onset age in PSP cases.
  • Type 2 statins (atorvastatin, rosuvastatin) were associated with lower scores on the PSP Rating Scale and Unified Parkinson's Disease Rating Scale, suggesting potential benefits for motor function.

Conclusions:

  • Statins may exhibit an inverse association with the risk and motor impairment in progressive supranuclear palsy (PSP).
  • These findings suggest a potential neuroprotective role for statins in PSP.
  • Randomized prospective studies are necessary to validate these observations and confirm the efficacy of statins in managing PSP.